Florida Biologix Announces Manufacturing Agreement with NanoSonic Products, Inc. to Formulate, Fill and Finish Trappsol Cyclo

ALACHUA, Fla.--(BUSINESS WIRE)--NanoSonic Products, Inc., a wholly owned subsidiary of CTD Holdings, Inc. (OTCQB:CTDH), and Florida Biologix have signed a contract for the formulation and fill of the sterile liquid form of its Trappsol Cyclo product, an FDA and EMEA designated orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer's, which affects children and adults and manifests with progressive neurological symptoms. Trappsol Cyclo is currently being administered in the U.S. under a compassionate use IND.